Skip to main content

Bio-Rad Laboratories, Inc. (BIO-B)

New York Stock Exchange Healthcare Medical - DevicesView data quality →
54.0Fair

ValueMarkers Composite Index

Top 51%#21,821 of 44,707

DCF data not available

Piotroski
5/9
Neutral
Beneish
-2.63
Low Risk
Altman
3.05
Safe
DCF Value
-
N/A
ROIC
1.7%
Low
P/E
10.2
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Bio-Rad Laboratories, Inc. (BIO-B) — VMCI valuation read

The headline on Bio-Rad Laboratories, Inc. (BIO-B) is a 54/100 VMCI score, set against a Healthcare sector median of 50. That 4-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

BIO-B insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** BIO-B trades at 23.0x earnings, 28% above the Healthcare median of 18.0x sets the value side. ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 3.0x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on BIO-B.

BIO-B fell 1.9% over the trailing 7 days, with a +0.9% read on a 30-day basis.

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO: Norman D. Schwartz7,700 employeesUSwww.bio-rad.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BIO-B’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.